Premium
A Pharmacological Analysis of Levonantradol Antinociception in Mice
Author(s) -
JACOB JOSEPH J.,
RAMABADRAN KRISHNASWAMI,
CAMPOSMEDEIROS MARY
Publication year - 1981
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1981.tb02611.x
Subject(s) - cyproheptadine , (+) naloxone , morphine , pharmacology , potency , antagonism , analgesic , chemistry , mechanism of action , serotonergic , medicine , antagonist , serotonin , receptor , in vitro , biochemistry
Using the hot plate test, the potency and mechanism of the analgesic activity of levonantradol was studied in mice. Levonantradol is 10 to 30 times more potent than morphine; the antinociception can be only partially blocked by naloxone. Similar limited antagonism by cholinergics indicates possible opiodergic mechanism. The role of serotoninergic pathways is unclear; antinociception is partially blocked by 5,7‐dihydroxytryptamine, unaffected by p ‐chlorophenylalanine, and potentiated by cyproheptadine. Levonantradol blocks naloxone‐induced signs of abstinence in morphine‐dependent mice, being 3000 times more potent than morphine and 300 times more potent than Δ 9 ‐tetrahydrocannabinol (THC).